secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0000950170-23-011178
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health FY2022 revenue $1.8M (+46% YoY); cash $3.5M, no debt
-----------------------------------------------------------------

- Revenue $1.8M (+46% YoY); direct-to-consumer sales $1.6M (+114%).
- Gross profit $299K vs gross loss of $38K in 2021; 9X gross margin improvement.
- Operating expenses: R&D $1.7M, S&M $2.8M, G&A $5.9M (total $10.4M).
- Cash $3.5M, no debt; used for operations and attempted acquisition of Reliefband.
- CEO cites supply chain challenges but expects growth in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023011178/0000950170-23-011178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023011178/tivc-20230331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-011178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer